FDA Publishes Complex Generics News Resource

August 5, 2022

Today the FDA is publishing a new web page to share the most recent FDA actions and activities related to complex generics. This new resource is part of FDA’s continued commitment to ensuring Americans have access to safe, effective, high-quality, and more affordable generic drugs.

Given FDA’s focus on regulatory and scientific initiatives to expand and strengthen this important area of our nation’s public health system, this page will be updated regularly with information about recent Agency actions related to complex generics, including:

  • notable approvals
  • guidance documents
  • research
  • events

Since these products are generally harder to develop, fewer exist, resulting in less market competition. This means that complex generics may be more expensive and less accessible to the patients who need them. Complex generics are a key component of FDA’s Drug Competition Action Plan, which aims to bring more drug competition to the market and address the high cost of medicines, and the Generic Drug User Fee Amendments, which include special provisions related to complex generics.

Complex Generics News Webpage

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.

TAGS:

Woman typing on laptop in an laboratory

April 2, 2012

GRAS List Substances: Background and Misconceptions

Although it is widely known that the acronym GRAS stands for “Generally Recognized as Safe”, many individuals believe that GRAS substances have been rigorously reviewed for safety and approved for...

Wayfinding signs with arrows showing 'right' and 'wrong.'

EMA Good clinical practice (GCP) inspection procedures

The Good Clinical Practice (GCP) Inspectors Working Group has developed procedures for the coordination, preparation, conduct and reporting of GCP inspections requested by the European Medicines...

Example of an submission process workflow.

February 24, 2014

Words, Words, Words: The Importance of Diction in Regulatory Submissions

In continuation of its series of guidances on electronic submissions, FDA recently released a guidance for receipt dates of electronic submissions which emphasizes one important fact: word choice...